Is There a “Blind Spot” in Point-of-Care Testing for Residual Heparin After Cardiopulmonary Bypass? A Prospective, Observational Cohort Study
Identifying the cause of a bleeding complication after cardiac surgery can be crucial. This study sought to clarify whether the application of unprocessed autologous pump blood influences anti-factor Xa activity after cardiac surgery and evaluated 2 point-of-care methods regarding their ability to i...
Main Authors: | Saskia Wand MD, Daniel Heise MD, Nadine Hillmann MD, Christian Bireta MD, Anselm Bräuer MD, Nicolas von Ahsen MD, Michael Quintel MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-08-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/1076029620946843 |
Similar Items
-
Heparin Coating Technology in Cardiopulmonary Bypass
by: Zhang Kun, et al.
Published: (2017-01-01) -
Biomarkers for Adverse Lung Injury Following Pediatric Cardiopulmonary Bypass
by: Ahmed Asfari, MD, et al.
Published: (2021-09-01) -
Brain and the rapid onset of hyponatremia during cardiopulmonary bypass
by: Ignazio Condello, PhD, et al.
Published: (2023-12-01) -
Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy
by: Emre Boysan, et al.
Published: (2023-09-01) -
Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass
by: Parissis Haralabos
Published: (2011-04-01)